ATA913976A - Verfahren zur herstellung von 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen - Google Patents

Verfahren zur herstellung von 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen

Info

Publication number
ATA913976A
ATA913976A AT913976A AT913976A ATA913976A AT A913976 A ATA913976 A AT A913976A AT 913976 A AT913976 A AT 913976A AT 913976 A AT913976 A AT 913976A AT A913976 A ATA913976 A AT A913976A
Authority
AT
Austria
Prior art keywords
16alfa
6alfa
17alfa
9alpha
11beta
Prior art date
Application number
AT913976A
Other languages
English (en)
Other versions
AT357703B (de
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25717430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA913976(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CH1615175A external-priority patent/CH621801A5/de
Priority claimed from LU75903A external-priority patent/LU75903A1/xx
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Priority to AT0081179A priority Critical patent/AT363200B/de
Priority to AT0081279A priority patent/AT363201B/de
Priority to AT81079A priority patent/AT363199B/de
Publication of ATA913976A publication Critical patent/ATA913976A/de
Application granted granted Critical
Publication of AT357703B publication Critical patent/AT357703B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT913976A 1975-12-12 1976-12-10 Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen AT357703B (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT0081179A AT363200B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha, 21-dihalogen-11beta, 17alpha-dihydroxy-6alpha-
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-
AT81079A AT363199B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-flour-16alpha-methyl-pregna-1,4-dien-3,20-dion-verbindungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1615175A CH621801A5 (en) 1975-12-12 1975-12-12 Process for the preparation of polyhalosteroids
LU75903A LU75903A1 (de) 1976-09-29 1976-09-29

Publications (2)

Publication Number Publication Date
ATA913976A true ATA913976A (de) 1979-12-15
AT357703B AT357703B (de) 1980-07-25

Family

ID=25717430

Family Applications (2)

Application Number Title Priority Date Filing Date
AT913976A AT357703B (de) 1975-12-12 1976-12-10 Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-

Country Status (16)

Country Link
US (1) US4619921A (de)
JP (1) JPS5289662A (de)
AT (2) AT357703B (de)
AU (1) AU508224B2 (de)
CA (1) CA1056371A (de)
DD (1) DD128683A5 (de)
DE (1) DE2655570A1 (de)
DK (1) DK143708C (de)
ES (1) ES454120A1 (de)
FR (1) FR2334363A1 (de)
GB (1) GB1537130A (de)
HU (1) HU175583B (de)
IE (1) IE44473B1 (de)
IL (1) IL51087A (de)
NL (1) NL7613791A (de)
NZ (1) NZ182836A (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209140B (it) * 1979-11-16 1989-07-10 Prochem Ets 6 alfa-fluoro-prednisolone 17,21-diesteri.
EP0078235A3 (de) * 1981-10-23 1983-06-29 Ciba-Geigy Ag Dihalogenierte Steroide
IT1319663B1 (it) * 2000-11-17 2003-10-23 Farmabios Srl Processo per la preparazione di fluoro-steroidi.
AU2002359523A1 (en) * 2001-11-29 2003-06-17 Taro Pharmaceuticals U.S.A., Inc. Method for the preparation of 6-alpha-fluoro corticosteroids
US20040138192A1 (en) * 2003-01-13 2004-07-15 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
NZ545748A (en) * 2003-08-29 2010-03-26 Ranbaxy Lab Ltd Isoxazoline derivatives as inhibitors of phosphodiesterase type-IV
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20070167420A1 (en) 2005-04-07 2007-07-19 Daniella Gutman Process for preparing a crystalline form of halobetasol propionate
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
EP1958947A1 (de) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitoren für Phosphodiesterase Typ 4
EP2124943A1 (de) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridinderivate als phosphodiesterasehemmer
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
DK3310389T3 (da) 2015-06-18 2020-08-10 Bausch Health Ireland Ltd Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB924931A (de) * 1958-07-09
US3499016A (en) * 1958-08-04 1970-03-03 Upjohn Co 6alpha-fluoro-16alpha-methyl derivatives of the pregnane series
GB898292A (en) * 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
CH534144A (de) * 1967-11-17 1973-02-28 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
US3718673A (en) * 1971-02-01 1973-02-27 Du Pont Process for the preparation of 21-chloro-6,6,9alpha-trifluoro-11beta, alpha, 17alpha-trihydroxy-1,4-pregnadien-3,20-dione 16,17-ketals and selected intermediates
US4018918A (en) * 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
US3992422A (en) * 1975-08-14 1976-11-16 Schering Corporation Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy-20-keto-pregnenes

Also Published As

Publication number Publication date
AU2047276A (en) 1978-06-15
HU175583B (hu) 1980-09-28
DK143708B (da) 1981-09-28
AT357703B (de) 1980-07-25
NZ182836A (en) 1979-01-11
IL51087A0 (en) 1977-02-28
ATA81279A (de) 1980-12-15
US4619921A (en) 1986-10-28
AT363201B (de) 1981-07-27
IE44473B1 (en) 1981-12-16
ES454120A1 (es) 1978-02-16
JPS5289662A (en) 1977-07-27
DD128683A5 (de) 1977-12-07
DE2655570A1 (de) 1977-06-16
DK143708C (da) 1982-03-15
GB1537130A (en) 1978-12-29
DK557876A (da) 1977-06-13
FR2334363B1 (de) 1980-03-14
AU508224B2 (en) 1980-03-13
CA1056371A (en) 1979-06-12
IL51087A (en) 1980-06-30
NL7613791A (nl) 1977-06-14
FR2334363A1 (fr) 1977-07-08
IE44473L (en) 1977-06-12

Similar Documents

Publication Publication Date Title
ATA913976A (de) Verfahren zur herstellung von 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen
AT338223B (de) Verfahren zur herstellung von tert.alkylathern
DD129334A5 (de) Verfahren zur herstellung von 4-androsten-3,17-dion-derivaten
ATA662376A (de) Verfahren zur herstellung von terpolymerisaten
ATA691077A (de) Verfahren zur herstellung von neuen 9alpha,21- -dihaolgen-11beta, 17alpha-dihydroxy-6alpha- -fluor-16beta-methyl-pregna-1,4- dien-3,20- -dion-verbindungen
AT338239B (de) Verfahren zur herstellung von 3-halogen- oder 3,5-dihalogenphenolen
AT346842B (de) Verfahren zur herstellung von 1,2-benz- isothiazolen
AT349454B (de) Verfahren zur herstellung von alfa-cyano- benzylestern
AT350558B (de) Verfahren zur herstellung von 2,4-dioxo- oxazolidinen
AT342294B (de) Verfahren zur herstellung von modifizierten, wasserverdunnbaren, carboxylgruppentragenden olefin-polymerolen
ATA980876A (de) Verfahren zur herstellung von 2-oxo-pyrrolidin- n-alkylamiden
AT339922B (de) Verfahren zur kontinuierlichen herstellung von 2,5-dioxo -1-oxa-2- phospholanen
AT351921B (de) Verfahren zur herstellung von bueroformularen
AT353411B (de) Verfahren zur herstellung von neuen 4- -dedimethylamino-4-arylsulfonamido-5a,6- -anhydrotetracyclinen
AT353989B (de) Verfahren zur herstellung von neuen 11,12- ungesaettigten 9alpha-fluorsteroiden
AT346299B (de) Verfahren zur herstellung von 6-acyloxy-4- methyl-hexa-2,4-dien-1-al
AT338220B (de) Verfahren zur herstellung von 1,1,2-trichlorathan
AT348506B (de) Verfahren zur herstellung von bis- polybromphenoxy-alkanen
AT343619B (de) Verfahren zur herstellung von propargylaminen
DD129333A5 (de) Verfahren zur herstellung von 4-androsten-3,17-dion-derivaten
ATA81079A (de) Verfahren zur herstellung von neuen 9alpha,21- -dihalogen-11beta,17alpha-dihydroxy-6alpha- -flour-16alpha-methyl-pregna-1,4-dien-3,20- -dion-verbindungen
AT342555B (de) Verfahren zur herstellung von neuen 2-methyl-3-buten-3-halogen-2-olen
AT347918B (de) Verfahren zur herstellung von hexachlor- cyclobuten
AT347462B (de) Verfahren zur herstellung von 2,6-diacyloxy- methyl-pyridinen
ATA238176A (de) Verfahren zur herstellung von cephalosporinen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee